+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

TNF Inhibitors - Global Strategic Business Report - Product Thumbnail Image

TNF Inhibitors - Global Strategic Business Report

  • Report
  • June 2026
  • 191 Pages
  • Global
From
Autoimmune Drugs - Global Strategic Business Report - Product Thumbnail Image

Autoimmune Drugs - Global Strategic Business Report

  • Report
  • June 2026
  • 287 Pages
  • Global
From
US Axial Spondyloarthritis Market outlook to 2028 - Product Thumbnail Image

US Axial Spondyloarthritis Market outlook to 2028

  • Report
  • October 2023
  • 85 Pages
  • United States
From
From
Antibody Drugs: Technologies and Global Markets - Product Thumbnail Image

Antibody Drugs: Technologies and Global Markets

  • Report
  • September 2024
  • 156 Pages
  • Global
From
Epilepsy Therapeutics Market Report 2024-2034 - Product Thumbnail Image

Epilepsy Therapeutics Market Report 2024-2034

  • Report
  • February 2024
  • 213 Pages
  • Global
From
From
Acute Repetitive Seizures - Global Strategic Business Report - Product Thumbnail Image

Acute Repetitive Seizures - Global Strategic Business Report

  • Report
  • June 2026
  • 180 Pages
  • Global
From
Levodopa Market - Global Strategic Business Report - Product Thumbnail Image

Levodopa Market - Global Strategic Business Report

  • Report
  • June 2026
  • 377 Pages
  • Global
From
Restless Legs Syndrome - Global Strategic Business Report - Product Thumbnail Image

Restless Legs Syndrome - Global Strategic Business Report

  • Report
  • June 2026
  • 290 Pages
  • Global
From
From
From
From
Epilepsy Drugs - Global Strategic Business Report - Product Thumbnail Image

Epilepsy Drugs - Global Strategic Business Report

  • Report
  • June 2026
  • 276 Pages
  • Global
From
From
Epilepsy Treatment - Global Strategic Business Report - Product Thumbnail Image

Epilepsy Treatment - Global Strategic Business Report

  • Report
  • June 2026
  • 483 Pages
  • Global
From
From
Loading Indicator